Clinical Trial Update: A Phase I Study of Pyrimethamine in Patients With GM2 Gangliosidosis [Phase 1]

View source ↗

Summary

A Phase I clinical trial of pyrimethamine for GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gm2 Gangliosidosis
• Sandhoff Disease
• Tay-sachs Disease

Drugs mentioned

• Pyrimethamine (Pyrimethamine)

Snippet

Sponsor: Exsar Corporation | Conditions: G(M2) Ganglioside, Tay-Sachs Disease Ganglioside | Phase 1 | Status: WITHDRAWN